TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07100106: A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Part

Sponsor: Genentech, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 285 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,806,420

Rescue Site Savings

+$1,178,100

Unlock Full NCT07100106 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07100106 Rescue Dossier →